Allogene Therapeutics, Inc (ALLO)

Etorro trading 970x250
Allogene Therapeutics, Inc (ALLO) Logo

About Allogene Therapeutics, Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080

Allogene Therapeutics, Inc News and around…

Latest news about Allogene Therapeutics, Inc (ALLO) common stock and company :

XLB, NIFE: Big ETF Outflows
18 Oct, 2021 FinancialContent

Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the The Materials Select Sector SPDR Fund, where 4,050,000 units were destroyed, or a 4.4% decrease week over week. Among the largest underlying components of XLB, in morning trading today Linde is off about 0.3%, and Sherwin-williams is lower by about 0.1%.

2 Top Healthcare Stocks That Could Be Bought Out in 2022
16 Oct, 2021 FinancialContent

These two novel-drug makers could be top takeover targets next year.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
16 Oct, 2021 Yahoo! Finance

Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

First Week of ALLO December 17th Options Trading
15 Oct, 2021 FinancialContent

Investors in Allogene Therapeutics Inc (ALLO) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALLO options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
15 Oct, 2021 FinancialContent

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
14 Oct, 2021 FinancialContent
Cathie Wood’s Ark Funds Built Up Big Stakes in Crispr Stock. The Stock Tumbled.
14 Oct, 2021 Yahoo! Finance

The ARK Innovation ETF and ARK Genomic Revolution ETF cumulatively snapped up hundreds of thousands of shares in Crispr in the past week.

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene
13 Oct, 2021 Yahoo! Finance

Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.

What 5 Analyst Ratings Have To Say About Allogene Therapeutics
12 Oct, 2021 FinancialContent

Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: Bullish Somewhat ...

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Intrinsic Value Is Potentially 96% Above Its Share Price
12 Oct, 2021 Yahoo! Finance

In this article we are going to estimate the intrinsic value of Allogene Therapeutics, Inc. ( NASDAQ:ALLO ) by...

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought
12 Oct, 2021 FinancialContent

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Allogene Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
11 Oct, 2021 Yahoo! Finance

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allogene Therapeutics, Inc. ("Therapeutics" or the "Company") (NASDAQ: ALLO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com,

Company News for Oct 11, 2021
11 Oct, 2021 Yahoo! Finance

Companies in The News Are: ACCD,CCXI,ALLO,WMT

Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?
11 Oct, 2021 Yahoo! Finance

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

35 Biggest Movers From Friday
11 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s ...

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
10 Oct, 2021 FinancialContent

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.

Noteworthy Friday Option Activity: RL, ALLO, ULTA
08 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ralph Lauren Corp (RL), where a total of 15,797 contracts have traded so far, representing approximately 1.6 million underlying shares. That amounts to about 204.9% of RL's average daily trading volume over the past month of 771,125 shares..

Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher
08 Oct, 2021 FinancialContent

Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, ...

ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
08 Oct, 2021 FinancialContent

The broader market was mixed on Friday.

Why Allogene Therapeutics Stock Is Getting Hammered Today
08 Oct, 2021 FinancialContent

A possible safety issue is crushing the biotech's shares today.

12 Health Care Stocks Moving In Friday's Intraday Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 ...

Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge
08 Oct, 2021 FinancialContent

Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, ...

Where Allogene Therapeutics Stands With Analysts
08 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: ...

28 Stocks Moving In Friday's Mid-Day Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) ...

Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021
08 Oct, 2021 FinancialContent

Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:NTRS) from Neutral to Buy. Northern Trust earned $1.79 in ...

Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
08 Oct, 2021 Yahoo! Finance

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September
08 Oct, 2021 FinancialContent

Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also ...

10 Biggest Price Target Changes For Friday
08 Oct, 2021 FinancialContent

Barclays cut the price target on Constellation Brands, Inc. (NYSE: STZ) from $260 to $257. Constellation Brands shares fell 0.3% to ...

Allogene Therapeutics, Inc (ALLO) is a NASDAQ Common Stock listed in , ,

970x250